Danicopan: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description| | {{Short description|Overview of the medication Danicopan}} | ||
{{Drugbox | {{Drugbox | ||
| verifiedfields = changed | | verifiedfields = changed | ||
| Line 10: | Line 10: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Danicopan | Danicopan works by inhibiting the activity of complement factor D, a serine protease that plays a crucial role in the activation of the [[alternative complement pathway]]. By blocking this pathway, Danicopan prevents the destruction of red blood cells, which is a hallmark of PNH. This mechanism helps to reduce hemolysis and improve the clinical symptoms associated with the disease. | ||
==Clinical Development== | ==Clinical Development== | ||
Danicopan is currently undergoing clinical trials to evaluate its efficacy | Danicopan is currently undergoing clinical trials to evaluate its safety and efficacy in patients with PNH. Early studies have shown promising results, with significant reductions in hemolysis markers and improvements in hemoglobin levels. The drug is being developed by [[Alexion Pharmaceuticals]], a company known for its focus on rare diseases. | ||
== | ==Potential Benefits== | ||
Danicopan | The use of Danicopan in PNH patients could offer several benefits, including: | ||
* Reduction in the need for blood transfusions | |||
* Improvement in quality of life | |||
* Decrease in the risk of thrombotic events | |||
==Side Effects== | ==Side Effects== | ||
As with any medication, Danicopan may cause side effects. Commonly reported adverse effects include: | |||
* Headache | |||
* Nausea | |||
* Fatigue | |||
Patients receiving Danicopan should be monitored for any signs of infection, as complement inhibition can increase susceptibility to certain infections. | |||
==Related pages== | ==Related pages== | ||
| Line 31: | Line 36: | ||
[[Category:Experimental drugs]] | [[Category:Experimental drugs]] | ||
[[Category:Immunology]] | [[Category:Immunology]] | ||
[[Category: | [[Category:Hematology]] | ||
Latest revision as of 21:00, 5 March 2025
Overview of the medication Danicopan
| Danicopan | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Danicopan is an investigational oral medication that acts as a complement factor D inhibitor. It is primarily being studied for its potential use in treating paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder.
Mechanism of Action[edit]
Danicopan works by inhibiting the activity of complement factor D, a serine protease that plays a crucial role in the activation of the alternative complement pathway. By blocking this pathway, Danicopan prevents the destruction of red blood cells, which is a hallmark of PNH. This mechanism helps to reduce hemolysis and improve the clinical symptoms associated with the disease.
Clinical Development[edit]
Danicopan is currently undergoing clinical trials to evaluate its safety and efficacy in patients with PNH. Early studies have shown promising results, with significant reductions in hemolysis markers and improvements in hemoglobin levels. The drug is being developed by Alexion Pharmaceuticals, a company known for its focus on rare diseases.
Potential Benefits[edit]
The use of Danicopan in PNH patients could offer several benefits, including:
- Reduction in the need for blood transfusions
- Improvement in quality of life
- Decrease in the risk of thrombotic events
Side Effects[edit]
As with any medication, Danicopan may cause side effects. Commonly reported adverse effects include:
- Headache
- Nausea
- Fatigue
Patients receiving Danicopan should be monitored for any signs of infection, as complement inhibition can increase susceptibility to certain infections.
